Clinical Trial: A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain

U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT07598448) titled 'A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain' on May 14.

Brief Summary: This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.

Study Start Date: May 16

Study Type: OBSERVATIONAL

Condition: Complement 3 Glomerulopathy

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Novartis Pharmaceuticals

Disclaimer: Curated by HT Syndication....